Direct angiotensin converting enzyme inhibitor-mediated venodilation

Clinical Pharmacology and Therapeutics

Volumn 59, Issue 5, 1996, Pages 559-568

  Zarnke, Kelly B ^a   Feldman, Ross D ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL MALEATE; ENALAPRILAT; GLYCERYL TRINITRATE; HUMAN INSULIN; NORADRENALIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; SKIN TEMPERATURE; VEIN COMPLIANCE; VEIN DILATATION;

ADULT; ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENALAPRILAT; FEMALE; HAND; HEART RATE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NITROGLYCERIN; NOREPINEPHRINE; STATISTICS; TEMPERATURE; VASODILATION; VEINS;

EID: 0029998445     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90184-8     Document Type: Article

References (44)

1. Materson BJ, Preston RA. Angiotensin-converting enzyme inhibitors in hypertension. Arch Intern Med 1994;154:513-23.
2. Kawamura M, Imanashi M, Matsushima Y, et al. Circulating angiotensin II levels under repeated administration of lisinopril in normal subjects. Clin Exp Pharmacol Physiol 1992;19:547-53.
3. Vanhoutte PM, Boulanger CM, Illiano SC, et al. Endothelium-dependent effects of converting-enzyme inhibitors. J Cardiovasc Pharmacol 1993;22(suppl 5): S10-6.
4. Webb DJ, Collier JG, Seidelin PH, et al. Regulation of regional vascular tone: the role of angiotensin conversion in human forearm resistance vessels. J Hypertens 1988;6 (suppl 3):S57-9.
5. Benjamin N, Cockcroft JR, Collier JG, et al. Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm. J Physiol 1989;412:543-55.
6. Auch-Schwelk W, Bossaller C, Claus M, et al. ACE inhibitors are endothelium dependent vasodilators of coronary arteries during submaximal stimulation with bradykinin. Cardiovasc Res 1993;27:312-7.
7. Auch-Schwelk W, Kuchenbuch C, Claus M, et al. Local regulation of vascular tone by bradykinin and angiotensin converting enzyme inhibitors. Eur Heart J 1993;14(suppl 1):154-60.
8. Auch-Schwelk W, Bossaller C, Claus M, et al. Local potentiation of bradykinin-induced vasodilation by converting-enzyme inhibition in isolated coronary arteries. J Cardiovasc Pharmacol 1992;20(suppl 9):S62-S67.
9. Busse R, Fleming I, Hecker M. Endothelium-derived bradykinin: implications for angiotensin-converting enzyme-inhibitor therapy. J Cardiovasc Pharmacol 1993;22(suppl 5):S31-6.
10. Dusing R, Scherhag R, Landsberg G, et al. The converting enzyme inhibitor captopril stimulates prostacyclin synthesis by isolated rat aorta. Eur J Pharmacol 1983;91:501-4.
11. van Gilst WH, van Wijngaarden J, Egbert E, et al. Captopril-induced increase in coronary flow: an SH-dependent effect on arachidonic acid metabolism? J Cardiovasc Pharmacol 1987;9(suppl 2):S31-6.
12. Nakamura M, Funakoshi T, Yoshida H, et al. Endothelium-dependent vasodilation is augmented by angiotensin converting enzyme inhibitors in healthy volunteers. J Cardiovasc Pharmacol 1992;20:949-54.
13. Eichler HG, Bloch-Daum B, Kyrle PA, et al. Cilazapril and enalapril inhibit local angiotensin I conversion in human veins but lack direct venodilating properties. J Cardiovasc Pharmacol 1989;14:248-52.
14. Goldschmidt JE, Tallarida RJ. Pharmacological evidence that captopril possesses an endothelium-mediated component of vasodilation: effects of sulfhydryl groups on endothelium-derived relaxing factor. J Pharmacol Exp Ther 1991;257:1136-45.
15. Lindpaintner K, Ganten D. The cardiac renin-angiotensin system: an appraisal of the current experimental and clinical evidence. Circ Res 1991;68:905-21.
16. Haber HL, Powers ER, Gimple LW, et al. Intracoronary angiotensin-converting enzyme inhibition improves diastolic function in patients with hypertensive left ventricular hypertrophy. Circulation 1994;89:2616-25.
17. Webb DJ, Collier JG. Influence of ramapril diacid on the peripheral vascular effects of angiotensin II. Am J Cardiol 1987;59:45D-9D.
18. Yang Z, Arnet U, von Segesser L, et al. Different effects of angiotensin-converting enzyme inhibition in human arteries and veins. J Cardiovasc Pharmacol 1993;22(suppl 5):S17-22.
19. Aellig WH. A new technique for recording compliance of human hand veins. Br J Clin Pharmacol 1981;11:237-43.
20. Aellig WH. Clinical pharmacology, physiology and pathophysiology of superficial veins; parts 1 and 2. Br J Clin Pharmacol 1994;38:181-196 and 289-305.
21. Feldman RD, Bierbrier GS. Insulin-mediated vasodilation: impairment with increased blood pressure and body mass. Lancet 1993;342:707-9.
22. Anderson GH, Streeton DHP. Norepinephrine inhibits acetylcholine but not nitroprusside induced vasodilation in human hand veins [Abstract]. Clin Res 1994;42:254A.
23. Hirsch AT, Talsness CE, Smith AD, et al. Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure. Circulation 1992;86:1566-74.
24. Donnelly R, Meredith PA, Elliott HL, et al. Kinetic-dynamic relations and individual responses to enalaprilat. Hypertension 1990;15:301-9.
25. Alradi AO, Carruthers SG. Evaluation and application of the linear variable differential transformer technique for the assessment of human dorsal hand vein alpha-receptor activity. Clin Pharmacol Ther 1985;38:495-502.
26. Luthra A, Borkowski KR, Carruthers SG. Genetic aspects of variability in superficial vein responsiveness to norepinephrine. Clin Pharmacol Ther 1991;49:355-61.
27. Nachev C, Collier J, Robinson B. Simplified method for measuring compliance of superficial veins. Cardiovasc Res 1971;5:147-56.
28. Pergola PE, Kellogg DL, Johnson JM, et al. Role of sympathetic nerves in the vascular effects of local temperature in human forearm skin. Am J Physiol 1993;265:H785-92.
29. Freedman RR, Sabharwal SC, Moten M, et al. Local temperature modulates alpha 1- and alpha 2-adrenergic vasoconstriction in men. Am J Physiol 1992;263:H1197-200.
30. Okamoto T, Iwase S, Sugenoya J, et al. Differential thermal dependency of cutaneous sympathetic outflow to glabrous and hairy skin in humans. Eur J Appl Physiol 1994;68:460-4.
31. Arner M, Hogestatt ED. Influence of temperature and extracellular pH on the contractile responses in isolated human hand veins. Pharmacol Toxicol 1990;67:141-6.
32. 2-adrenergic-mediated vasoconstriction in human hand veins. Acta Physiol Scand 1990;138:283-91.
33. Saruta T, Suzuki H, Okuno T, et al. Effects of angiotensin-converting enzyme inhibitors on the vascular response to norepinephrine. Am J Cardiol 1982;49:1535-6.
34. Foult JM, Tavolaro O, Anthony I, et al. Coronary vasodilation induced by intracoronary enalaprilat: an argument for the role of a local renin-angiotensin system in patients with dilated cardiomyopathy. Eur Heart J 1989;10(suppl F):97-100.
35. Bank AJ, Kubo SH, Rector TS, et al. Local forearm vasodilation with intra-arterial administration of enalaprilat in humans. Clin Pharmacol Ther 1991;50:314-21.
36. Hecker M, Dambacher T, Busse R. Role of endothelium-derived bradykinin in the control of vascular tone. J Cardiovasc Pharmacol 1992;20(suppl 9): S55-61.
37. Iimura O, Shimamoto K. Role of kallikrein-kinin system in the hypotensive mechanisms of converting enzyme inhibitors in essential hypertension. J Cardiovasc Pharmacol 1989;13(suppl 3):S63-6.
38. Iimura O, Shimamoto K. Significance of kallikrein-kinin and renin-angiotensin-I systems in the hypotensive mechanisms of angiotensin-I converting enzyme inhibitors in essential hypertensives. Adv Exp Med Biol 1989;247A:39-48.
39. Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994;23:439-49.
40. Tio RA, Heiligers JPC, de Langen CDJ, et al. The hemodynamic effects of two angiotensin converting enzyme inhibitors, enalaprilat and zofenoprilat, in the rat: evidence for the involvement of bradykinin. J Hypertens 1989;7(suppl 6):S296-7.
41. Collier JG, Lorge RE, Robonson BF, et al. Comparison of the effects of tolmesoxide (RX71107), diazoxide, hydralazine, prasozin, glyceryl trinitrate and sodium nitroprusside on forearm arteries and dorsal hand veins of man. Br J Clin Pharmacol 1978;5:35-44.
42. Eichler HG, Hiremath A, Katzir D, Blaschke TF, Hoffman BB. Absence of age-related changes in venous responsiveness to nitroglycerin in vivo in humans. Clin Pharmacol Ther 1987;42:521-4.
43. Lui AS, Arnold JMO. Difference between peripheral venous volume-pressure responses to sublingual nitroglycerine [Abstract]. Clin Pharmacol Ther 1992;51:171.
44. Krauss SL, Dodge JT, Bevan JA. Magnitude of β-adrenoreceptor-mediated responses of dog epicardial coronary arteries: inverse relation to diameter. Am J Physiol 1992;263(5 pt 2):H1422-9.